Medical Care Technologies Inc Stock Price, News & Analysis

Medical Care Technologies (OTC Pink: MDCE) on October 7, 2025 announced a strategic split of its AI health platform into two divisions: a Clinical AI Division targeting FDA-eligible modules and formal validation, and a Consumer AI Division for general wellness and research apps.

The Clinical Division lists dermatological screening, ocular/retinal analytics, and wound monitoring as modules intended for regulatory pathways such as FDA 510(k) or De Novo, with planned validation studies and pre-submission work in upcoming quarters. The Consumer Division will deliver non-diagnostic wellness tools like mental health trackers and lifestyle scoring for apps and research partnerships.

Medical Care Technologies (OTC PINK:MDCE) on October 6, 2025 said it will benchmark an upcoming AI diagnostic model against the HAM10000 public dermatology dataset to validate its image recognition architecture for detecting multiple skin lesion types.

The company said the HAM10000 data will be used under a research license to assess model precision, sensitivity, and specificity relative to peer‑reviewed standards as part of an ongoing proof‑of‑concept development. Management framed this as aligning performance metrics with academic standards and noted risks including data variability, integration challenges, and evolving regulatory guidance.

Medical Care Technologies (OTC PINK:MDCE) announced on October 3, 2025 that it is exploring blockchain technology as a security framework for patient medical data in its upcoming medical research app. The company says blockchain is being evaluated to enhance protection of sensitive health information while designing for full HIPAA compliance from day one.

The app will turn smart devices into personalized AI health assistants using photos, voice scans, facial metrics and other non‑invasive inputs. A beta release is scheduled for 2026, with initial tests focused on security protocols, database integrity, and user experience.

Medical Care Technologies (OTC Pink:MDCE) has secured access to the International Skin Imaging Collaboration (ISIC) Archive, one of the world's largest public skin cancer image databases. The archive contains over 70,000 dermoscopic images with expert annotations across various skin tones and cancer types.

This database will be used to train MDCE's AI software for detecting and classifying melanoma and other skin cancers. With skin cancer being the most common cancer globally (1.5 million new cases annually), this development aims to improve early detection capabilities worldwide.

The company is currently integrating the ISIC data into its machine learning pipeline and exploring additional collaborations to expand its training image database as it progresses toward clinical trials and commercialization.

Medical Care Technologies Inc. (OTC PINK:MDCE) announced a leadership transformation under CEO Marshall Perkins, following his remarkable recovery from advanced bone cancer and vitiligo in early 2025. After months of hospitalization and a challenging recovery process that affected his vertebrae and mobility, Perkins has made a full recovery.

Now recovered, Perkins is leading MDCE's initiatives in healthcare innovation, working with a team of medical experts, students, and technology innovators to develop preventative healthcare solutions. The company aims to create value for both patients and shareholders through its focus on healthcare monitoring and optimization technologies.

Medical Care Technologies (OTC:MDCE) has launched an innovative AI Facial Health Risk Estimator designed to detect diabetic retinopathy in its early stages. The technology analyzes facial images to identify retinal abnormalities such as microaneurysms, hemorrhages, and vascular leakage, offering a non-invasive screening solution.

CEO Marshall Perkins emphasized that this AI-powered system aims to address the challenge of late diagnosis in diabetic retinopathy, which is a leading cause of preventable blindness globally. The technology promises to improve accessibility to early screening and enhance patient outcomes through early detection.

Medical Care Technologies (OTC:MDCE) has enhanced its AI Facial Health Risk Estimator platform to include detection capabilities for glaucoma and cataracts. The expanded platform now analyzes high-resolution facial and ocular images to identify corneal opacity, lens clouding, and early optic nerve changes.

The integration creates a comprehensive preventive care solution by combining eye health monitoring with existing systemic and dermatological metrics. CEO Marshall Perkins emphasized the platform's holistic approach to early detection of vision-threatening conditions.

Medical Care Technologies (OTC:MDCE) has announced the development of an innovative AI Facial Health Risk Estimator for early diabetes detection. The technology analyzes facial biomarkers including skin tone irregularities, microvascular patterns, and elasticity loss to predict Type 2 diabetes risk before clinical diagnosis.

The non-invasive system uses predictive algorithms to assess diabetes susceptibility through facial analysis, potentially enabling earlier interventions and better patient outcomes, according to CEO Marshall Perkins.

Medical Care Technologies (OTC:MDCE) has unveiled its innovative AI Facial Health Risk Estimator, a technology designed to detect early cardiovascular disease risks through advanced facial imaging analysis.

The system employs deep neural networks to analyze biometric markers including micro-wrinkle density, skin elasticity, and tone variations. By comparing biological age against chronological age, the platform can identify cardiovascular predisposition before clinical symptoms appear, offering a non-invasive alternative to traditional testing methods.